scholarly journals Efficiency of prognostic scales in assessing patients' condition in severe acute pancreatitis

2020 ◽  
Vol 5 (4) ◽  
pp. 278-282
Author(s):  
I. V. Makarov ◽  
I. A. Mustafaev ◽  
A. V. Kurashev ◽  
L. A. Budorina ◽  
L. V. Gerasimov

Objectives to compare the predictive efficiency of modern scales used in prognosis of disease severity (APACHE II, SAPS, SOFA, MODS) in patients with severe acute pancreatitis. Material and methods.17 patients formed two study groups: Group 1 consisted of 10 survived patients, Group 2 included 7 patients with a fatal outcome. The mortality ratio and the severity of the condition were calculated for all 17 patients, using the scales presented above, at the admission to the ICU and at the moment of transfer to a surgical department. The intensive care procedure and surgical interventions were in line with the clinical recommendations for surgical treatment of severe acute pancreatitis. Results.The day of ICU admission, Group 1, the average mortality rate on the SAPS scale was 110.08%; on the SOFA scale 270.08%; on the MODS scale 12%; on the APACHE II scale 8.450.09%. The day of ICU admission, Group 2, the average mortality rate on the SAPS scale was 5.77.11%; on the SOFA scale 25.146.09%; on the MODS scale 2.41.05%; on the APACHE II scale 12.18.49%. The day of patients' transfer from the ICU to the surgical department, Group1, the average mortality rate on the SAPS scale was 8.990.10%; on the SOFA scale 300.15%; on the MODS scale 12%; on the APACHE II scale 14.290.08%. The day of patients' transfer from the ICU to the surgical department, Group 2, the average mortality rate on the SAPS scale was 7.78.69%; on the SOFA scale 220%; on the MODS scale 12%, on the APACHE II scale 12.379.89%. According to our data, none of the used prognostic scales could present the real condition of a patient or the mortality prognosis for patients in both groups. By comparison of the average mortality rate calculated for patients of Group 1 and Group 2, we revealed the more unfavorable prognosis for the survived patients than for the patients with lethal outcome. Conclusion.The objective evaluation of the severity of patient's condition and the prognosis for treatment is not possible with the scales used in the study. Among them, the SAPS and APACHE II scales provided the most precise prognoses for patients' condition.

2021 ◽  
Vol 8 (8) ◽  
pp. 2281
Author(s):  
Hector Losada M. ◽  
Sonia Curitol ◽  
Andres Troncoso T. ◽  
Norberto Portillo L.

Background: Acute pancreatitis is a frequent disease in Chile, with mortality rate of 10-30%. Prophylactic antibiotics administration has been part of severe acute pancreatitis treatment for theoretical prevention of infectious complications and mortality reduction. Yet the available evidence is controversial. The aim of the study was to demonstrate that prophylactic antibiotics do not reduce complications, need for intensive care unit bed or mortality in severe acute pancreatitis.Methods: Randomized clinical trial with simple randomization using a computational table (use or non-use of prophylactic antibiotics) of patients with severe acute pancreatitis. We define severe acute pancreatitis as APACHE II ≥8, C-reactive protein ≥150. In prophylactic antibiotics use group, ciprofloxacin and metronidazole were administered for 7 days. This preliminary report is presented with 50% of the calculated sample.Results: N=150, two randomized groups; group 1 (n=73), without prophylactic antibiotics use, and group 2 (n=77) with antibiotic prophylaxis use. Twenty-four patients (16%) required intensive care unit bed; twelve in group 1, and twelve in group 2 (p=0.53). Ten patients (6.66%) had some type of complication, one in group 1 and nine in group 2 (p=0.01). The average hospital stay was 15.7±9.0 days in group 1, and 16.8±17.9 days in group 2 (p=0.57). Mortality was four patients (2.66%), one in group 1 and three in group 2 (p=0.33).Conclusions: In this preliminary report, the prophylactic antibiotics use for severe acute pancreatitis was not shown to reduce complications, need for an intensive care unit bed or mortality.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5836-5836
Author(s):  
Ana Carolina Oliver ◽  
Eloisa Riva ◽  
Ricardo Fabian Mosquera ◽  
Silvia Pierri ◽  
Sebastian Galeano ◽  
...  

Abstract Introduction: Autologous stem cell transplant (ASCT) plays a central role in the treatment of diverse diseases. Infection is one of the major causes of morbidity and costs of the procedure, representing the 2ndcause of death (24%) after primary disease (69%). Thus, preventing infections is a major goal.1There are no publications concerning infections in ASCT in our country. Patients and Methods: Retrospective single center study. Objectives: to compare the incidence of febrile neutropenia (FN) and characteristics of infections between 2 different antibacterial approaches. From January 2006 - December 2017, 279 ASCT have been done in our center. We included 266 patients with complete data: 249 received 1 ASCT and 17 received two. Anti-bacterial prophylaxis from 2006-2013 (Group 1) was ciprofloxacin from day 0 to neutrophil recovery. From 2013 to present (Group 2), levofloxacin was used. First febrile episode empirical treatment was Ceftazidime-Amikacin in Group 1 and Meropenem in Group 2. Results: Median age was 56 years (18-72). MM and NHL (79,7%), 40% in complete remission, were the prevailing diseases. Median CD34+ cells transplanted was 4,87 x 106/kg (0,88-37). Median duration of neutropenia was 11 days (9-32). (Table 1) Group 1: 28% had no FN episodes. Catheter-related and gastrointestinal were the most prevalent sites of infection. Positive cultures were 17,4%, 66,6% Gram+. 91% received Ceftazidime+Amikacine. A 2ndantibiotic was added in 52 patients (60%). Six patients required intensive care unit (ICU) admission (4.9%), due to pneumonia (3), sepsis (2) and viral encephalitis (1). Median days at discharge after ASCT was 17 (10-56); 20,6 for those who had FN episodes and 16,5 for those who did not (p= 0,004). Group 2: 13,8 % had no FN episodes. Pneumonia and catheter-related infections were the most prevalent sites of infection. Positive cultures: 20 %; 69% Gram +. 70 patients received an additional agent (56%).Six patients required ICU admission (4,1%), 1 due to pneumonia, 1 sepsis, 1 alitiasic cholecystitis, 1 catheter-related infection and pneumonia, 1 bradyarrhythmia and 1 atrial fibrillation. Median days at discharge after ASCT was +16 (12-62), 19,8 for those who experienced FN and 17 for those who did not (p=0,184). Incidence of FN was 72% in Group 1 and 86,2% in Group 2 (p=0,004). Culture-negativity was 82,6% in Group 1 and 80% in Group 2. In blood + cultures, Gram + agents represented 66.6% in Group 1 and 69% in Group 2 (p=0.68). Discussion: FN is common in ASCT (63-94%)2,3, implying longer hospitalization, more diagnostic procedures and increase in morbidity and mortality. Significant differences in FN incidence between groups, in favor of Ciprofloxacin prophylaxis (72% vs 86,2% (p=0,004) were found. The incidence of positive cultures was similar in both groups. Gram+ agents were the most common isolation. Prophylaxis with quinolones leaded to a low Gram negative bacteria isolation, as reported by others.4Most infectious episodes were associated with fever of unknown origin: 53 % in Group 1 and 56.8 % in Group 2, with differences in sites of infection's frequency: catheter-related infection prevailed in Group 1 and pneumonia in Group 2. (Table 2) We hypothesized that a better Gram+ coverage with Levofloxacin might have help to reduce the incidence of clinical catheter infections. A 2nd antibiotic was needed in 60% from Group 1 and 56% in Group 2 (p=0,47). Median to neutrophil recovery was shorter in Group 1 (+8 vs +10), (p=0,0001). ICU admission was mostly due to sepsis, similar in both groups (p=0,74). During hospitalization, 2 patients died of sepsis in Group 1 and 0 in Group 2. Mortality rate was 1,87 %, similar to international reports.5 Patients in Group 2 were older, with more advanced diseases and hypogammaglobulinemia, which may contribute to difference in favor of Ciprofloxacin group in terms of FN and days to hematopoiesis recovery. (Table 3) Levofloxacin prophylaxis was not associated with an increase in resistant bacteria nor Clostridium difficile infection. Conclusions: The incidence of FN in ASCT was high. Levofloxacin prophylaxis was associated with more FN episodes and later discharge. Epidemiology and severity of infections and 2nd antibiotic requirement were comparable in both groups. Patients admitted for ASCT in the last 7 years had additional risk features that may contribute to explain the differences found. Mortality rate was low in both groups. Disclosures No relevant conflicts of interest to declare.


Author(s):  
O. K. Khalidov ◽  
V. S. Fomin ◽  
A. N. Gudkov ◽  
G. O. Zayratyants ◽  
G. P. Dmitrienko ◽  
...  

Aim. To evaluate an effectiveness of non-invasive stimulation of gastrointestinal peristaltic activity in complex correction of motor-evacuation disorders and intra-abdominal hypertension in patients with severe acute pancreatitis.Material and methods. There were 85 patients with severe acute pancreatitis. Patients were divided into two groups: group 1 (n = 43) – percutaneous resonance stimulation; group 2 (n = 42) – routine treatment of acute pancreatitis with intraperitoneal hypertension syndrome and dynamic intestinal obstruction according to normative documents. Intra-abdominal pressure was measured in 1, 3, 5, 7 days after disease onset. Abdominal perfusion pressure and filtration gradient were additionally calculated. Moreover, outcomes were assessed after 1, 3, 5, and 7 days according to visual-analogue scale.Results. There were faster regression of intraperitoneal hypertension followed by normalization of abdominal pressure after 7 days in group 1 compared with group 2 (p ≤ 0.05). Data of visual-analogue scale confirmed patients’ good tolerability of resonance stimulation including absent local discomfort during electrodes deployment and better state of health compared with group 2 (p ≤ 0.05). Infectious complications rate was 20.9% in group 1, 38.1% – in group 2. Sepsis developed in 3 (7%) patients of group 1 and in 7 (16.6%) patients of group 2. Overall mortality was 7% and 14.3% in both groups, respectively. Сonclusion. Percutaneous resonance stimulation is able to improve outcomes in patients with severe acute pancreatitis.


2020 ◽  
Vol 4 (9) ◽  
pp. 539-543
Author(s):  
D.T. Chipova ◽  
◽  
L.V. Santikova ◽  
A.Ch. Zhemukhov ◽  
◽  
...  

Aim: to study the stroke-associated pneumonia (SAP) effect on the outcome of ischemic stroke (IS) in the internal carotid artery system. Patients and Methods: 87 patients with IS underwent the follow-up study, of which 75 had no inflammatory bronchopulmonary complications (group 1), and 12 had pneumonia manifestation (group 2). The study was performed on days 1, 5, and 9 after IS, and 6 months and 12 months after discharge from the hospital. Neurological deficit severity (NIHSS, Barthel index) and inflammatory markers (peripheral blood leukocyte composition, C-reactive protein (CRP), ESR) were studied. Results: it was found that the presence of SAP was associated with increased mortality during the acute IS period (4 (33.1%) patients died in group 1 and 10 (13.3%) — in group 2, p<0.05), greater severity of neurological deficits (63.3±5.3 and 71.5±4.0 points on the NIHSS scale, respectively, p<0.05) and incapacitation (Barthel index — 63.3±5.3 and 71.5±4.0 points, respectively, p<0.05) at the end of the inpatient treatment period. In group 2, signs of an inflammatory response were detected on day 5, and the values of the white blood cell shift index, ESR and CRP significantly (p<0.05) differed from the initial values. During examination at 6 months and 12 months, there were no significant differences in these indicators between the groups. An association was established between the probability of SAP occurrence and the presence of swallowing disorders (r=0.672; p<0.05), the age of patients (r=0.572; p<0.05) and the presence of diabetes mellitus (r=0.522; p<0.05). The studied laboratory inflammatory markers allow us to timely assume the occurrence of pulmonary pathology. Conclusion: timely diagnosis and prevention of SAP can reduce the risk of fatal outcome, facilitate rehabilitation measures, and improve early IS outcomes. KEYWORDS: ischemic stroke, cardioembolic stroke, atherothrombotic stroke, complications, acute period, inflammatory markers, strokeassociated pneumonia, long-term outcomes. FOR CITATION: Chipova D.T., Santikova L.V., Zhemukhov A.Ch. Impact of stroke-associated pneumonia on the outcome of acute ischemic stroke in internal carotid artery system. Russian Medical Inquiry. 2020;4(9):539–543. DOI: 10.32364/2587-6821-2020-4-9-539-543.


2012 ◽  
Vol 28 (1) ◽  
Author(s):  
Ratendar Kumar Singh ◽  
Parnadi Bhaskar Rao ◽  
Arvind Kunar Baronia ◽  
Banani Poddar ◽  
Afzal Azim ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4000-4000
Author(s):  
Miklos Udvardy ◽  
Attila Kiss ◽  
Bela Telek ◽  
Robert Szasz ◽  
Peter Batar ◽  
...  

Abstract Bortezomib (Velcade) proved to be the standard element of refractory myeloma 2nd and 3rd line treatment, while many studies are suggesting excellent results in 1st line. Proteasome inhibition, the block of angiogenesis, modification of the NF-kappa-B system seems to be a challenging target in other malignant diseases, including refractory acute myeloid leukemia (AML), as well. In vitro data clearly support, that bortezomib exerts antiproliferative and pro-apoptotic effects in different AML cell-lines, along with human AML cell cultures, and moreover bortezomib was able to restore, or at least improve anthracyclin and possibly ARA-C sensitivity in different cell-lines (including AML). More recently, a Phase I trial showed bortezomib monotherapy efficient (only in few percents) in childhood refractory acute leukemia. Some case reports were shown at ASH 2007. We have tried bortezomib containing first or second line combinations in 27 (14 female, 13 male, mean age 57.6 years) patients with refractory or poor risk AML, in a small retrospective survey. The combinations were as follows: HAM or Flag-Ida, combined with bortezomib 1,3 mg pro sqm, day O and seven). The following groups were considered as refractory or poor risk AML: De novo AML, 2nd line: No response/remission to first line standard treatment (“3+7”), n=2 (Velcade- Flag-Ida treatment) De novo AML 1st line: bilineal or biphenotypic (flow-cytometry) n=2 (Velcade-Flag- Ida treatment) De novo AML with complex (numerical or more than 3 abnormalities) karyotype or normal karyotype with flt-3 TKD mutation, n=9, 1st line (Velcade-Flag-Ida n=6, Velcade- HAM protocol, n=3) Secondary AML or AML with evidence of previous more than 6 mo duration high grade MDS, n=14, 1st line: (Velcade-Flag-Ida n=9, Velcade-HAM n=5) RESULTS: Complete remission (CR) 12/27, partial remission (PR) 9/27, no remission 5/27, progression during treatment: 1/27.Best responses were seen in de novo cases. CR had been achieved in all patients of group 1 (two standard risk patients not responding to 3+7 protocol), and group 2 (biphenotypic, bilineal). The CR rate was quite appreciable in group 3, i.e. 6/9 (complex karyotype or normal karyotype with FLt-3 mutation – the response rate was excellent with flt-3 mutated cases). In group 4. (MDS, secondary AML) the results were less impressive. There were no major differences according to protocol (Flag-Ida or HAM) Allogeneous stem cell transplantation could have been performed in 1st CR in two patients (one from group 1. and another from group 2.). One of them died due to relapse, the other one is in CR since then. The combinations seem to be relatively safe. Induction related death rate was low (1 elderly patient acute thrombocytopenic bleeding with refractory MDS-AML). 5 other patients had severe neutropenic sepsis (2 with fatal outcome). Pulmonary syndrome, which may follow Velcade+ARA-C had not been documented. Other adverse events did not differ from the pattern observed with standard induction therapies.


2008 ◽  
Vol 43 (11) ◽  
pp. 1387-1396 ◽  
Author(s):  
Chie Morioka ◽  
Masahito Uemura ◽  
Tomomi Matsuyama ◽  
Masanori Matsumoto ◽  
Seiji Kato ◽  
...  

Author(s):  
Dr. Ajay Khanolkar ◽  
Dr. Manish Khare

Aim of study: - To assess the utility of each as prognostic indicator in Severe Acute Pancreatitis. Material and Methods: This prospective study entitled “To assess the utility of each as prognostic indicator in Severe Acute Pancreatitis” was carried out on patients hospitalized for acute pancreatitis in the surgery department at Chandulal Chandrakar Memorial Medical College and CM Hospital, Bhilai from March 2015 to October 2017.50 patients with the diagnosis of first attack of acute pancreatitis of both sexes and all age groups were selected for the study. Conclusion:- On the basis of observation and result of the study, it can be safely stated that APACHE II Scoring is quick, safe, reproducible, ongoing and cost effective. It can be done by resident or intelligent nursing staff. Give an idea regarding improving or worsening of patients. APACHE II Scoring system when complimented by high quality CECT abdomen can further refine the results and give an idea of likelihood of patients developing local complication. Thus it can also be used along with CECT abdomen for Risk Stratification of subset of patients who are likely to develop local complication who might need surgical intervention. CECT on 3rd day adds nothing to management. It has a tendency to over predict the regional complication, which are in anyway apart of natural course of history of disease (acute fluid collection). Management decision could not be based on CECT abdomen on 3rd day alone, since it is not needed to make a diagnosis of acute pancreatitis it should be abundant, thus reducing the financial burden of patients and institute. CECT abdomen done after 2nd week in the course of illness along with APACHE II Score and clinical finding are better guide for management and surgical intervention.


Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 2013
Author(s):  
Tudorel Mihoc ◽  
Cristi Tarta ◽  
Ciprian Duta ◽  
Raluca Lupusoru ◽  
Greta Dancu ◽  
...  

Acute pancreatitis is an unpredictable disease affecting the pancreas and it is characterized by a wide range of symptoms and modified lab tests, thus there is a continuing struggle to classify this disease and to find risk factors associated with a worse outcome. The main objective of this study was to identify the risk factors associated with the fatal outcome of the intensive care unit’s patients diagnosed and admitted for severe acute pancreatitis, the secondary objective was to investigate the prediction value for the death of different inflammatory markers at the time of their admission to the hospital. This retrospective study included all the patients with a diagnosis of acute pancreatitis admitted to the Intensive Care Unit of the Emergency County Hospital Timisoara between 1 January 2016 and 31 May 2021. The study included 53 patients diagnosed with severe acute pancreatitis, out of which 21 (39.6%) survived and 32 (60.4%) died. For the neutrophils/lymphocytes ratio, a cut-off value of 12.4 was found. When analyzing age, we found out that age above 52 years old can predict mortality, and for the platelets/lymphocytes ratio, a cut-off value of 127 was found. Combining the three factors we get a new model for predicting mortality, with an increased performance, AUROC = 0.95, p < 0.001. Multiple persistent organ failure, age over 50, higher values of C reactive protein, and surgery were risk factors for death in the patients with severe acute pancreatitis admitted to the intensive care unit. The model design from the neutrophils/lymphocytes ratio, platelets/lymphocytes ratio, and age proved to be the best in predicting mortality in severe acute pancreatitis.


2005 ◽  
Vol 133 (1-2) ◽  
pp. 76-81 ◽  
Author(s):  
Maja Surbatovic ◽  
Krsta Jovanovic ◽  
Sonja Radakovic ◽  
Nikola Filipovic

Acute pancreatitis is an inflammatory process which occurs in severe form in 20% of all patients, out of whom 1596-25% will die. The incidence of severe acute pancreatitis-associated lung injury (APALI) varies from 15% to 55% and its severity varies from mild hypoxemia to acute respiratory distress syndrome (ARDS). Acute lung injury (ALI) and ARDS are the most significant manifestations of extra abdominal dysfunctions in severe acute pancreatitis with mortality rate as high as 60% in the first week of the onset of illness. Different pathophysiological mechanisms of severe acute pancreatitis-associated lung injury have been described. The role of enzymes, adhesion molecules, neutrophils, fibronectin and various inflammatory mediators has been emphasized. Mechanism of the acute lung injury associated with the acute pancreatitis is very complex and has not been clear yet. There is no specific therapeutic procedure and mortality rate is very high. Therefore, further studies are necessary to address this acute and growing problem in intensive medicine.


Sign in / Sign up

Export Citation Format

Share Document